|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's Range||12.90 - 12.90|
|52 Week Range||8.88 - 23.55|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Small-cap biotech Replimune's lead asset RP1, a genetically modified herpes virus that serves to boost the virus' ability to kill tumor cells, is likely to be successful, Driscoll said in the Wednesday initiation note.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don’t follow. Because of their pay structures, they have strong incentive to do the research necessary […]
Investment company Bain Capital Life Sciences Investors, LLC buys Replimune Group Inc during the 3-months ended 2018-09-30, according to the most recent filings of the investment company, Bain Capital ...
Biotech Replimune Group, Inc. (NASDAQ: REPL ), which conducts research and cancer treatment studies using oncolytic viruses, picked up a sell-side bull Tuesday. The Analyst BMO Capital Markets analyst ...